Target Price | $158.10 |
Price | $168.16 |
Deviation | 5.98% |
Number of Estimates | 34 |
34 Analysts have issued a price target Arm 2026 . The average Arm target price is $158.10. This is 5.98% lower than the current stock price. The highest price target is $220.50 31.13% , the lowest is $80.80 51.95% . | |
A rating was issued by 39 analysts: 24 Analysts recommend Arm to buy, 13 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Arm stock has an average upside potential 2026 of 5.98% . Most analysts recommend the Arm stock at Purchase. |
39 Analysts have issued a sales forecast Arm 2026 . The average Arm sales estimate is $4.8b . This is 17.13% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $6.1b 46.98% , the lowest is $4.4b 5.58% .
This results in the following potential growth metrics:
2025 | $4.0b | 23.94% |
---|---|---|
2026 | $4.8b | 20.46% |
2027 | $5.9b | 21.44% |
2028 | $6.9b | 17.60% |
2029 | $9.1b | 31.38% |
2030 | $11.7b | 29.57% |
2031 | $15.4b | 31.42% |
2032 | $14.6b | 5.06% |
26 Analysts have issued an Arm EBITDA forecast 2026. The average Arm EBITDA estimate is $2.3b . This is 139.56% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $2.9b 202.91% , the lowest is $1.8b 87.95% .
This results in the following potential growth metrics and future EBITDA Margins:
2025 | $916m | 364.97% |
---|---|---|
2026 | $2.3b | 151.86% |
2027 | $2.9b | 26.01% |
2028 | $3.9b | 35.29% |
2029 | $5.1b | 28.40% |
2030 | $6.0b | 19.45% |
2031 | $7.6b | 25.76% |
2025 | 22.86% | 275.16% |
---|---|---|
2026 | 47.79% | 109.06% |
2027 | 49.59% | 3.77% |
2028 | 57.05% | 15.04% |
2029 | 55.76% | 2.26% |
2030 | 51.40% | 7.82% |
2031 | 49.19% | 4.30% |
36 Analysts have issued a Arm forecast for earnings per share. The average Arm EPS is $1.72 . This is 160.61% higher than earnings per share in the financial year 2025. The highest EPS forecast is $2.23 237.88% , the lowest is $1.40 112.12% .
This results in the following potential growth metrics and future valuations:
2025 | $0.75 | 158.62% |
---|---|---|
2026 | $1.72 | 129.33% |
2027 | $2.30 | 33.72% |
2028 | $2.87 | 24.78% |
2029 | $3.69 | 28.57% |
2030 | $4.59 | 24.39% |
2031 | $5.64 | 22.88% |
2032 | $5.40 | 4.26% |
Current | 254.79 | 0.93% |
---|---|---|
2026 | 97.86 | 61.59% |
2027 | 73.27 | 25.13% |
2028 | 58.61 | 20.01% |
2029 | 45.53 | 22.32% |
2030 | 36.67 | 19.46% |
2031 | 29.84 | 18.63% |
2032 | 31.12 | 4.29% |
Based on analysts' sales estimates for 2026, the Arm stock is valued at an EV/Sales of 37.12 and an P/S ratio of 37.72 .
This results in the following potential growth metrics and future valuations:
Current | 43.48 | 2.01% |
---|---|---|
2026 | 37.12 | 14.62% |
2027 | 30.57 | 17.66% |
2028 | 25.99 | 14.97% |
2029 | 19.79 | 23.88% |
2030 | 15.27 | 22.82% |
2031 | 11.62 | 23.91% |
2032 | 12.24 | 5.33% |
Current | 44.18 | 1.88% |
---|---|---|
2026 | 37.72 | 14.63% |
2027 | 31.06 | 17.66% |
2028 | 26.41 | 14.97% |
2029 | 20.10 | 23.88% |
2030 | 15.52 | 22.82% |
2031 | 11.81 | 23.91% |
2032 | 12.44 | 5.33% |
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Oct 09 2025 |
Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Sep 11 2025 |
Seaport Global |
➜
Buy
|
Initiated | Aug 11 2025 |
Rosenblatt |
Buy
➜
Buy
|
Unchanged | Jul 31 2025 |
Needham |
Hold
➜
Hold
|
Unchanged | Jul 31 2025 |
Keybanc |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Oct 09 2025 |
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Sep 11 2025 |
Initiated
Seaport Global:
➜
Buy
|
Aug 11 2025 |
Unchanged
Rosenblatt:
Buy
➜
Buy
|
Jul 31 2025 |
Unchanged
Needham:
Hold
➜
Hold
|
Jul 31 2025 |
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Jul 31 2025 |
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jul 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.